ArticleFrontiers in neurology
A prognostic model incorporating MCP-1 and IL-8 for early risk stratification in acute ischemic stroke patients receiving intravenous thrombolysis: a retrospective development with temporal validation.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the expression characteristics of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) in patients with acute ischemic stroke (AIS) who received intravenous thrombolysis and their relationship with clinical prognosis. Methods: This retrospective study included 300 patients with AIS who received intravenous thrombolysis. Patients were chronologically divided into a development cohort ( Results: Within the AIS cohort, MCP-1 and IL-8 levels were significantly higher in the poor outcome group compared with the good outcome group (both Conclusion: MCP-1 and IL-8 are independent prognostic biomarkers in AIS patients treated with intravenous thrombolysis. Their sustained elevation and combined use in a clinical prediction nomogram significantly enhance early risk stratification, offering a potential tool for personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.